With evolving standards for handling hazardous drugs, nurses must comply with safety and handling guidelines.

The most powerful thing we offer is not a medication or a skill: it’s presence. Presence steadies a hand during uncertainty ...

Coiro, an advanced practice nurse practitioner at the John Theurer Cancer Center at Hackensack University Medical Center Stem ...

Kristin Daly, MSN, ANP-BC, AOCNP, shares advice for preparing patients for possible adverse effects outside of clinic hours.

The FDA has converted its 2024 accelerated approval of tarlatamab-dlle (Imdelltra) for the treatment of adults with extensive ...

The multi-day nature of standard chemotherapy regimens used in extensive-stage small cell lung cancer (ES-SCLC) creates ...

Luspatercept-aamt (Reblozyl) is among National Comprehensive Cancer Network Guideline recommendations for low-risk MDS.

Biomarker testing for patients with ovarian cancer should be completed both in the upfront setting and through disease ...

Panelists discuss how effective caregivers should join support groups, maintain detailed records of symptoms and medications, attend all appointments, stay informed about myeloma research, and serve ...

Panelists discuss how expectations for treatment outcomes can become more positive over time through experience with multiple therapies, staying informed about clinical trials and new treatments, and ...

The FDA has approved a biosimilar of pertuzumab that is indicated for multiple breast cancer settings. The FDA has approved a biosimilar of pertuzumab-dpzb biosimilar (Perjeta) called Poherdy, which ...

Panelists discuss how healthcare providers must actively educate local oncologists, emergency departments, and community centers about bispecific antibody management as these therapies move from ...